Prometic Life Scie Com Npv (NASDAQ:PFSCF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “ProMetic Life Sciences Inc. is a biopharmaceutical company. The company is involved in bioseparations, plasma-derived therapeutics and small-molecule drug development. Its operating segment consists of Therapeutics and Protein Technology. Therapeutics segment products include PBI-4050 for treatment of fibrosis with chronic kidney diseases, certain cancers and side effects associated with chemotherapy; PBI-4419, an anti-fibrotic and anti-inflammatory compound for kidney injury and chronic kidney diseases and PBI-1402 for the treatment of anemia indications. Protein Technology segment provides plasma protein purification system, bioseparation products and prion capture/pathogen removal technology platform. ProMetic Life Sciences Inc. is headquartered in Laval, Canada. “
Prometic Life Scie Com Npv (NASDAQ:PFSCF) opened at 2.3392 on Wednesday. The firm’s 50 day moving average price is $2.24 and its 200-day moving average price is $2.33. Prometic Life Scie Com Npv has a 12-month low of $1.29 and a 12-month high of $2.77. The stock’s market cap is $1.41 billion.